Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| C4 Therapeutics, Inc.CCCC · Entity 5503 | Director | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
C4 Therapeutics, Inc.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 79,471 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 4,618 · Balance 79,471 F1: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.
F2: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 1, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MOMENTA PHARMACEUTICALS INC
Report date October 01, 2020 · Filed October 01, 2020
Section 16 reporting ended · disclosed 2020-10-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.52 · Expires 2029-09-18 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-10-01 · Disposition to issuer · Disposed 50,000 · Balance 0 F1: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.09 · Expires 2030-06-23 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-10-01 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 3, 2026 00:43 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 4,618 | $3.14 | $14,500.52 |
DisclosureSEC source: 0001470831-26-000924 · wk-form4_1790973819.xml · nonDerivative · entry 1 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,471 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 1, 2026. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:04 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 3,341 | $4.34 | $14,499.94 |
DisclosureSEC source: 0001470831-26-000689 · wk-form4_1783022677.xml · nonDerivative · entry 1 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,853 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 1, 2026. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 20:25 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 62,000 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001470831-26-000657 · wk-form4_1782505541.xml · derivative · entry 1 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 62,000 shares Expires 2036-06-23 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 14:45 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 5,370 | $2.70 | $14,499.00 |
DisclosureSEC source: 0001470831-26-000345 · wk-form4_1775227541.xml · nonDerivative · entry 1 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,512 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 1, 2026. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:10 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 7,513 | $1.93 | $14,500.09 |
DisclosureSEC source: 0001470831-26-000008 · wk-form4_1767647408.xml · nonDerivative · entry 1 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,142 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on January 2, 2026. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:13 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 6,740 | $2.15 | $14,491.00 |
DisclosureSEC source: 0001470831-25-000249 · wk-form4_1759522434.xml · nonDerivative · entry 1 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,629 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 1, 2025. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:17 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 9,609 | $1.51 | $14,509.59 |
DisclosureSEC source: 0001662579-25-000052 · wk-form4_1751487418.xml · nonDerivative · entry 1 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,889 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 1, 2025. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 20:11 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 35,500 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001662579-25-000044 · wk-form4_1750450260.xml · derivative · entry 1 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,500 Underlying: Common Stock · 35,500 shares Expires 2035-06-17 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2026 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:11 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 9,581 | $1.44 | $13,748.74 |
DisclosureSEC source: 0001662579-25-000025 · wk-form4_1743711105.xml · nonDerivative · entry 1 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,280 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 1, 2025. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:08 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 3,757 | $3.66 | $13,750.62 |
DisclosureSEC source: 0001662579-25-000004 · wk-form4_1735938506.xml · nonDerivative · entry 1 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,699 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on January 2, 2025. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 20:32 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 2,474 | $5.56 | $13,755.44 |
DisclosureSEC source: 0001662579-24-000090 · wk-form4_1727901151.xml · nonDerivative · entry 1 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,942 F1 · shares: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 1, 2024. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:14 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 2,836 | $4.85 | $13,754.60 |
DisclosureSEC source: 0001662579-24-000064 · wk-form4_1719951273.xml · nonDerivative · entry 1 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,468 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 1, 2024. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 20:06 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 32,500 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0001662579-24-000054 · wk-form4_1719000392.xml · derivative · entry 1 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2034-06-19 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 20, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 20:33 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 1,697 | $8.10 | $13,745.70 |
DisclosureSEC source: 0001662579-24-000036 · wk-form4_1712089991.xml · nonDerivative · entry 1 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,632 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 1, 2024. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 21:10 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 2,108 | $6.52 | $13,744.16 |
DisclosureSEC source: 0001662579-24-000004 · wk-form4_1704316184.xml · nonDerivative · entry 1 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,935 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on January 2, 2024. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 20:26 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 8,089 | $1.70 | $13,751.30 |
DisclosureSEC source: 0001662579-23-000107 · wk-form4_1696364777.xml · nonDerivative · entry 1 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,827 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 2, 2023. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 20:23 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 4,858 | $2.83 | $13,748.14 |
DisclosureSEC source: 0001662579-23-000066 · wk-form4_1688588615.xml · nonDerivative · entry 1 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,738 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 3, 2023. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:23 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001662579-23-000058 · wk-form4_1686946972.xml · derivative · entry 1 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 15, 2024 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 20:19 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 4,298 | $3.20 | $13,753.60 |
DisclosureSEC source: 0001662579-23-000044 · wf-form4_168063950739832.xml · nonDerivative · entry 1 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,880 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 3, 2023. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 21:17 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 1,763 | $6.38 | $11,247.94 |
DisclosureSEC source: 0001662579-23-000005 · wf-form4_167286698318570.xml · nonDerivative · entry 1 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,582 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on January 3, 2023. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 22:06 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 819 | $8.69 | $7,117.11 |
DisclosureSEC source: 0001662579-22-000006 · wf-form4_166492116846862.xml · nonDerivative · entry 1 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 819 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 3, 2022. Read SEC document |
| July 29, 2022 Filed Aug 2, 2022 20:24 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 41,200 | $0.00 Strike: $9.64 | $0.00 |
DisclosureSEC source: 0001209191-22-043870 · doc4.xml · derivative · entry 1 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,200 Underlying: Common Stock · 41,200 shares Expires 2032-07-28 F1 · derivative.exercise_date: One-third of the shares underlying this option shall vest and become exercisable on July 29, 2023, with the remainder vesting in eight equal quarterly installments thereafter. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 17:15 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $38.09 | Not disclosed |
DisclosureSEC source: 0001179110-20-010062 · edgar.xml · derivative · entry 2 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2030-06-23 F1 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option. F1 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 17:15 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $13.52 | Not disclosed |
DisclosureSEC source: 0001179110-20-010062 · edgar.xml · derivative · entry 1 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2029-09-18 F1 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option. F1 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 17:45 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $38.09 | $0.00 |
DisclosureSEC source: 0001179110-20-007752 · edgar.xml · derivative · entry 1 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-06-23 F1 · derivative.exercise_date: Represents an option granted by the Company pursuant to the Company's 2013 Incentive Award Plan. The stock option will vest and become exercisable on the first anniversary of the grant date, subject to Dr. Grogan's continued service to the Company. Read SEC document |
| September 18, 2019 Filed Sep 20, 2019 17:09 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $13.52 | $0.00 |
DisclosureSEC source: 0001179110-19-010523 · edgar.xml · derivative · entry 1 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-09-18 F1 · shares: Represents options granted by the issuer pursuant to the issuer's 2013 Incentive Award Plan. F2 · derivative.exercise_date: The stock option will vest and become exercisable with respect to 16,667 shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent two years. All vesting is subject to Dr. Grogan's continued service to the Company through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.